Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study

Jeffrey M. Hardacre,Mary Frances Mulcahy,William Small,Mark S. Talamonti,Jennifer Obel,Smitha S. Krishnamurthi,Caio S. Rocha-Lima,Howard Safran,Heinz J. Lenz,E. Gabriela Chiorean

Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: A Phase 2 Study

2013

Jeffrey M. Hardacre
Mary Frances Mulcahy
William Small
Mark S. Talamonti
Jennifer Obel
Smitha S. Krishnamurthi
Caio S. Rocha-Lima
Howard Safran
Heinz J. Lenz
E. Gabriela Chiorean

Background Despite continued investigation, limited progress has been made in the adjuvant treatment of resected pancreatic cancer. Novel or targeted therapies are needed.

Keywords:

Adjuvant therapy
Phases of clinical research
Adjuvant
Pancreatic cancer
Immunotherapy
General surgery
Oncology
Algenpantucel-L
Medicine
Internal medicine
Pancreatectomy
Chemotherapy
Chemoradiotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

132

Citations